Sanpraz - pharmacological agents from the group of proton pump inhibitors for the treatment of ulcerative lesions of the gastrointestinal tract.
Structure and Composition
According Sanpraz instructions issued in the form of tablets, coated in form of a lyophilisate for intravenous administration. The active ingredient - pantoprazole.
Sanpraza Tablets round, biconcave, yellow coated enteric-coated. 1 tablet contains 40 mg of pantoprazole and auxiliary components (magnesium oxide, crospovidone, calcium carbonate, sodium lauryl sulfate, calcium stearate, colloidal silicon dioxide, crospovidone. Polymethacrylate, triethyl citrate, talc, macrogol, titanium dioxide, isopropyl alcohol, water).
Sanpraz as a lyophilisate is available in glass vials. In one vial (10 ml) contains 40 mg of pantoprazole. A packing to the bottle attached lyophilisate ampoule with a solvent (sodium chloride and water) 10 ml. In a cardboard box 1 vial of lyophilisate and 1 vial of solvent.
Pharmacological action Sanpraza
According to the instructions Sanpraz is a proton pump inhibitor, the drug inhibits secretion of hydrochloric acid in its final stage, and thus affects the basal and stimulated secretion. Application Sanpraza the treatment of peptic ulcer disease associated with Helicobacter, enhances the sensitivity of the microorganism to antibiotics. Sanpraz no effect on the motility of the digestive system. The secretory activity of the stomach is reduced after taking this drug in 3 days.
According to the instructions Sanpraz has no cumulative effect. Withdrawal of the drug in the kidneys.
- the treatment of peptic ulcer disease (chronic gastric ulcer or duodenal ulcer in the acute stage);
- treatment of erosive changes in gastric mucosa and duodenal ulcers (acute ulcers of various origins, erosive gastritis);
- erosive reflux esophagitis, gastroesophageal reflux disease (GERD);
- pancreatic gastrinoma (Zollinger-Ellison syndrome);
- prevention of erosive and ulcerative complications of the digestive system in the early postoperative period in patients with an increased risk.
- Hypersensitivity to the ingredients of the drug;
- malignant neoplasms of the digestive tract;
- digestive disorders of psychogenic origin;
- lactation, children under 18 years.
Caution should be used during pregnancy Sanpraz and signs of liver failure.
Use during pregnancy and lactation
In clinical tests on animals revealed slight embryotoxic effect. Therefore, the use Sanpraza during pregnancy is possible only if the potential benefit outweighs the risk to the fetus. No data on the penetration Sanpraza into breast milk. It is recommended to stop breast-feeding during treatment with this drug.
Dosing and Administration Sanpraza
According to the instructions Sanpraz tablets should be taken 1-2 times a day, without chewing, drinking plenty of water. The preparation should be applied for 1 hour before a meal. Admission Sanpraza, reviews, well tolerated and effectively eliminates clinical symptoms.
In the treatment of peptic ulcer disease and erosive lesions of the mucosa of the upper gastrointestinal tract Sanpraz recommended to take 40-80 mg per day for 14 days. If necessary, treatment may be extended to 4-8 weeks (after consulting a doctor).
In the treatment of reflux oesophagitis Sanpraz assigned 40 mg (1 tablet) once daily for 4-6 weeks.
In patients with impaired liver function Sanpraza dose should not exceed 20-40 mg per day (the drug can be taken in a day) during treatment is necessary to monitor the biochemical parameters of blood (bilirubin, ALT, AST, alkaline phosphatase).
Sanpraz as a lyophilisate for solution is only intended for intravenous administration. The usual dose of the drug administered is 40 mg (1 bottle) per day. Course duration intravenous infusions of 7-10 days, followed by a switch to oral Sanpraza.
In the treatment of Zollinger - Ellison and other pathological states of the hypersecretion of hydrochloric acid Sanpraza daily dose may be increased to 80 mg (administered 2 times a day). The maximum daily dose of 160 mg of the drug.
Elderly patients Sanpraza recommended daily dose is 40 mg.
The lyophilizate, which should be mixed with the solvent (10 ml). The resulting solution is infused bolus (over 2-5 minutes) or when the drip infusion (mixed with 100 ml physiological sodium chloride solution or 5% glucose solution).
According to reviews, Sanpraz rarely causes adverse reactions at the recommended doses.
The following side effects: headache, nausea, abdominal pain, diarrhea / constipation, bloating. In the opinion of Sanpraz rarely cause dry mouth, depression, joint pain, hallucinations (in predisposed patients).
In very rare cases, the drug caused an allergic reaction (including anaphylactic shock), hepatic failure, interstitial nephritis, leukopenia, thrombocytopenia, severe skin reactions (Lyell's syndrome, Stevens-Johnson syndrome).
No reports of overdose with this drug in humans. The dosage administered to 240 mg per day were well tolerated. Treatment of overdose - symptomatic.
Interaction with other drugs
According Sanpraz instructions may reduce the absorbability of drugs whose bioavailability is directly linked to the acidity of gastric juice (e.g. ketokonazol, ritonavir, iron salts).
While the use of warfarin was an increase in prothrombin time, which may cause bleeding. Therefore, a combination of these two drugs must monitor the prothrombin time.
With drugs such as digoxin, metoprolol, nifedipine, diclofenac, fenazol, piroxicam, naproxen, amoxicillin, clarithromycin, glibenclamide, diazepam, karbmazepin, cisapride, midazolam, metronidazole, theophylline has been detected clinically significant interaction.
Sanpraza analogues are drugs from the group of proton pump inhibitors: pantoprazole, zipantola, nolpaza, kontrolok, Pantazi, pizhenum-sanovel. Before replacing analogue Sanpraza should consult a doctor.
Before the treatment of gastric ulcer should exclude the possibility of a malignant nature of the process, since treatment can Sanprazom grease clinical picture and delay correct diagnosis. Be sure to conduct endoscopic control before and after treatment Sanprazom, it would eliminate the malignant tumors of the upper digestive system and will assess the effectiveness of the therapy.
The drug does not affect the ability to drive vehicles.